Tiziana appoints dr. kevin schutz as vice-president of regulatory affairs

New york and london, june 21, 2021 (globe newswire) -- tiziana life sciences plc (nasdaq: tlsa, lse: tils), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, is pleased to announce the appointment of dr. kevin schutz, pharmd, as vice-president of regulatory affairs. dr. schutz will lead regulatory interactions related to clinical studies in the united states, europe and asian countries.
TLSA Ratings Summary
TLSA Quant Ranking